BioSpace News Archive

The first and only genomic test to achieve “Recommended” status for the management of prostate cancer patients

Collaboration between Triumvira Immunologics and Lonza will leverage the innovative Cocoon® Platform for novel TAC01-HER2 program

scPharmaceuticals Inc. announced financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.

Non-Latex® Tourniquets with Antimicrobial Product Protection include an antimicrobial agent to make them resistant to microbes such as bacteria, mold, and fungi.*

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a second Phase 1 human clinical trial for INM-755 in healthy volunteers.

3M and Ford will collaborate on making more powered air purifying respirators to help in the fight against the COVID-19 outbreak

DiaCarta Inc., a precision molecular diagnostic company, announced today that it has filed for Emergency Use Authorization (EUA) with the US FDA for its QuantiVirus™ SARS-CoV-2 test and has validated the COVID-19 diagnostic test in its own CLIA certified lab in Richmond, CA to provide testing services for healthcare providers an

ReWalk Robotics Ltd. a global leader in Exoskeleton technology for community use and rehabilitation centers, issued the following letter to shareholders

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored Phase 1/2 clinical trial of the company’s GAS6/AXL inhibitor AVB-500 in combination with PD-L1 inhibitor avelumab in patients with advanced urothelial carcinoma (UC). The study is being led by Abhishek Tripathi, M.D., Assistant Professor of Medicine, Section of hematology/oncology at the University of

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on March 30, 2020, to review its financial results for the fourth quarter and full-year ended December 31, 2019 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for t